Paracetamol in critical illness: A review

Critical Care and Resuscitation

Volumn 14, Issue 1, 2012, Pages 74-80

  Jefferies, Sarah ^a,b   Saxena, Manoj ^c   Young, Paul ^a,b  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b WELLINGTON HOSPITAL   (New Zealand)

^c ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIPYRETIC AGENT; PARACETAMOL;

CRITICAL ILLNESS; DRUG TOXICITY; HUMAN; REVIEW;

ACETAMINOPHEN; ANALGESICS; ANTIPYRETICS; CRITICAL ILLNESS; DRUG TOXICITY; HUMANS;

EID: 84864012530     PISSN: 14412772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Brune K. The early history of non-opioid analgesics. Acute Pain 1997; 1: 33-40.
2. Drews J. Drug discovery: a historical perspective. Science 2000; 287: 1960-4.
3. Morse HN. Ueber eine neue darstellungsmethode des acetylamidophenole [A new method of preparing acetomidophenole]. Ber Dtsch Chem Ges 1878; 11: 232-3.
4. Cahn A, Hepp P. Das antifebrin, ein neues fiebermittel [Antifebrin, a new antipyretic]. Zentralbl Klin Med 1886; 33: 561-4.
5. Drugs discovered through serendipity in the laboratory. In: Sneader W. Drug discovery: a history. New York: John Wiley & Sons, 2005: 438-9.
6. Hinsberg O, Kast A. Ueber die wirkung des acetphenetidins [About the workings of the acetphenetidins]. Centralb Med Wissensch 1887; 25: 145.
7. von Mering J. Beitrage zur kenntniss der antipyretica [Adding to the understanding of antipyretics]. Ther Monatsch 1893; 7: 577-87.
8. Hinsberg O, Treupel G. Ueber die physiologische wirkung des pamidophenols und einiger derivate desselben [About the physiological workings of the p-amidophenols and similar derivatives]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1894; 33: 216-50.
9. Witthauer K. Aspirin, eine neues salicylpräparat [Aspirin, a new salicylate preparation]. Die Heilkunde 1899; 3: 396-8.
10. Brodie BB, Axelrod J. The estimation of acetanilide and its metabolic products, aniline, N-acetyl p-aminophenol and p-aminophenol (free and total conjugated) in biological fluids and tissues. J Pharmacol Exp Ther 1948; 94: 22-8.
11. Brodie BB, Axelrod J. The fate of acetanilide in man. J Pharmacol Exp Ther 1948; 94: 29-38.
12. Lester D, Greenberg LA, Carroll RP. The metabolic fate of acetanilid and other aniline derivatives: II. Major metabolites of acetanilid appearing in the blood. J Pharmacol Exp Ther 1947; 90: 68-75.
13. Greenberg LA, Lester D. The metabolic fate of acetanilid and other aniline derivatives III. The role of p-aminophenol in the production of methemoglobinemia after acetanilid. J Pharmacol Exp Ther 1947; 90: 150-3.
14. Flinn FB, Brodie BB. The effect on the pain threshold of N-acetyl p-aminophenol, a product derived in the body from acetanilide. J Pharmacol Exp Ther 1948; 94: 76-7.
15. Spooner JB, Harvey JG. The history and usage of paracetamol. J Int Med Res 1976; 4: 1-6.
16. Brodie BB, Axelrod J. The fate of acetophenetidin (phenacetin) in man and methods for the estimation of acetophenitidin and its metabolites in biological material. J Pharmacol Exp Ther 1949; 97: 58-61.
17. Fifield MM. Renal disease associated with prolonged use of acetophenetidin-containing compounds. N Engl J Med 1963; 269: 722-6.
18. Jacobs LA, Morris JG. Renal papillary necrosis and the abuse of phenacetin. Med J Aust 1962; 49: 531-8.
19. Moolten SE, Smith IB. Fatal nephritis in chronic phenacetin poisoning. Am J Med 1960; 28: 127-34.
20. Dubach UC, Rosner B, Stürmer T. An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). N Engl J Med 1991; 324: 155-60.
21. Michielsen P, de Schepper P. Trends of analgesic nephropathy in two high-endemic regions with different legislation. J Am Soc Nephrol 2001; 12: 550-6.
22. Arrowsmith JB, Kennedy DL, Kuritsky JN, Faich JA. National patterns of aspirin use and Reye syndrome reporting, United States, 1980 to 1985. Pediatrics 1987; 79: 858-63.
23. Bertolini A, Ferrari A, Ottani A, et al. Paracetamol: new vistas of an old drug. CNS Drug Rev 2006; 12: 250-75.
24. Mattia A, Coluzzi F. What anesthesiologists should know about paracetamol (acetaminophen). Minerva Anestesiologica 2009; 75: 644-53.
25. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972; 240: 410-1.
26. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl 1996; 102: 9-21.
27. Lucas R, Warner TD, Vojnovic I, Mitchell JA. Cellular mechanisms of acetaminophen: role of cyclo-oxygenase. FASEB J 2005; 19: 635-7.
28. Boutaud O, Aronoff DM, Richardson JH, et al. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc Natl Acad Sci U S A 2002; 99: 7130-5.
29. Clissold SP. Paracetamol and phenacetin. Drugs 1986; 32 Suppl 4: 46-59.
30. Ouellet M, Percival MD. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch Biochem Biophys 2001; 387: 273-80.
31. Aronoff DM, Neilson EG. Antipyretics: mechanisms of action and clinical use in fever suppression. Am J Med 2001; 111: 304-15.
32. Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 2006; 79: 9-19.
33. Graham GG, Scott KF. Mechanism of action of paracetamol. Am J Ther 2005; 12: 46-55.
34. Högestätt ED, Jönsson BA, Ermund A, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 2005; 280: 31405-12.
35. Beltramo M, Stella N, Calignano A, et al. Functional role of highaffinity anandamide transport, as revealed by selective inhibition. Science 1997; 277: 1094-7.
36. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004; 74: 1317-24.
37. Ovadia H, Wohlman A, Mechoulam R, Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 1995; 34: 175-80.
38. Ottani A, Leone S, Sandrini M, et al. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol 2006; 531: 280-1.
39. Raffa RB, Stone DJ Jr, Tallarida RJ. Discovery of "self-synergistic" spinal/supraspinal antinociception produced by acetaminophen (paracetamol). J Pharmacol Exp Ther 2000; 295: 291-4.
40. Raffa RB, Walker EA, Sterious SN. Opioid receptors and acetaminophen (paracetamol). Eur J Pharmacol 2004; 503: 209-10.
41. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41: 1135-51.
42. Zagli G, Tarantini F, Bonizzoli M, et al. Altered pharmacology in the intensive care unit patient. Fundam Clin Pharmacol 2008; 22: 493-501.
43. Landzinski J, Kiser TH, Fish DN, et al. Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. JPEN J Parenter Enteral Nutr 2008; 32: 45-50.
44. Berger MM, Werner D, Revelly JP, et al. Serum paracetamol concentration: an alternative to x-rays to determine feeding tube location in the critically ill. JPEN J Parenter Enteral Nutr 2003; 27: 151-5.
45. Berger MM, Berger-Gryllaki M, Wiesel PH, et al. Intestinal absorption in patients after cardiac surgery. Crit Care Med 2000; 28: 2217-23.
46. Beck DH, Schenk MR, Hagemann K, et al. The pharmacokinetics and analgesic efficacy of larger dose rectal acetaminophen (40 mg/ kg) in adults: a double-blinded, randomized study. Anesth Analg 2000; 90: 431-6.
47. de Maat MM, Tijssen TA, Brüggemann RJ, Ponssen HH. Paracetamol for intravenous use in medium-and intensive care patients: pharmacokinetics and tolerance. Eur J Clin Pharmacol 2010; 66: 713-9.
48. Greenberg RS, Hegang, C, Hasday JD. Acetaminophen has limited antipyretic activity in critically ill patients. J Crit Care 2010; 25: 363. e2-.37.
49. Schulman CI, Namias N, Doherty J, et al. The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study. Surg Infect (Larchmt) 2005; 6: 369-75.
50. den Hertog H, van der Worp H, van Gemert H, et al. The Paracetamol (Acetominophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol 2009; 8: 434-40.
51. Dippel DW, van Breda EJ, van der Worp HB, et al. Timing of the effect of acetaminophen on body temperature in patients with acute ischemic stroke. Neurology 2003; 61: 677-9.
52. Australian New Zealand Clinical Trials Registry. Trial details. The Paracetamol After traumatic Brain Injury Study. 2011. http:// www.anzctr.org.au/trial_view.aspx?ID=83959 (accessed Jun 2011).
53. Baena RC, Busto R, Dietrich WD, et al. Hyperthermia delayed by 24 hours aggravates neuronal damage in rat hippocampus following global ischemia. Neurology 1997; 48: 768-73.
54. Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. Stroke 1998; 29: 529-34.
55. Morimoto T, Ginsberg MD, Dietrich WD, Zhao W. Hyperthemia enhances spectrin breakdown in transient focal cerebral ischemia. Brain Res 1997; 746: 43-51.
56. Greer DM, Funk SE, Reaven NL, et al. Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive metaanalysis. Stroke 2008; 39: 3029-35.
57. National Stroke Foundation. Clinical guidelines for stroke management 2010. Melbourne: NSF, 2010.
58. Saxena M, Andrews PJ, Cheng A. Modest cooling therapies (35 degrees C to 37.5 degrees C) for traumatic brain injury. Cochrane Database Syst Rev 2008; (3): CD006811.
59. Enders JF, Shaffer MF. Studies on natural immunity to pneumococcus type III. J Exp Med 1936; 64: 7-18.
60. Oxford JS, Corcoran T, Schild GC. Naturally occurring temperaturesensitive influenza A viruses of the H1N1 and H3N2 subtypes. J Gen Virol 1980; 48: 383-9.
61. Kiang JG, Tsokos GC. Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther 1998; 80: 183-201.
62. Roberts NJ Jr. Impact of temperature elevation on immunologic defences. Rev Infect Dis 1991; 13: 462-72.
63. Bryant RE, Hood AF, Hood CE, Koenig MG. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med 1971; 127: 120-8.
64. Weinstein MP, Iannini PB, Stratton CW, Eickhoff TC. Spontaneous bacterial peritonitis. A review of 28 cases with emphasis on improved survival and factors influencing prognosis. Am J Med 1978; 64: 592-8.
65. Doran TF, De Angelis C, Baumgardner RA, Mellits ED. Acetaminophen: more harm than good for chickenpox? J Pediatr 1989; 114: 1045-8.
66. Brandts CH, Ndjave M, Graninger W, Kremsner PG. Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet 1997; 350: 704-9.
67. Graham NM, Burrell CJ, Douglas RM, et al. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990; 162: 1277-82.
68. Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374: 1339-50.
69. Young P, Saxena M, Eastwood GM, et al. Fever and fever management among intensive care patients with known or suspected infection: a multicentre prospective cohort study. Crit Care Resusc 2011; 13: 97-102.
70. Jefferies S, Weatherall M, Young P, et al. The effect of antipyretic medications on mortality in critically ill patients with infection: a systematic review and meta-analysis. Crit Care Resusc 2011; 13: 125-31.
71. Greisman SE. Cardiovascular alterations during fever. In: Mackowiak PA, editor. Fever: basic mechanisms and management. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1997: 143-65.
72. Gozzoli V, Treggiari MM, Kleger GR, et al. Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response. Intensive Care Med 2004; 30: 401-7.
73. Schug SA, Manopas A. Update on the role of non-opioids for postoperative pain treatment. Best Pract Res Clin Anaesthesiol 2007; 21: 15-30.
74. Barden J, Edwards J, Moore A, McQuay H. Single dose oral paracetamol (acetaminophen) for postoperative pain. Cochrane Database Syst Rev 2004; (4): CD004602.
75. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30: 119-41.
76. Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet 2010; 375: 475-80.
77. Elia N, Lysakowski C, Tramer MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology 2005; 103: 1296-304.
78. Maund E, McDaid C, Rice S, et al. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. Br J Anaesth 2011; 106: 292-7.
79. Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth 2005; 94: 505-13.
80. Paracetamol. In: Young P. Critical care drug manual. Perth: Life in the Fast Lane, 2010. http://lifeinthefastlane.com/book/critical-caredrugs/ paracetamol (accessed May 2011).
81. Lahtinen P, Kokki H, Hendolin H, et al. Propacetamol as adjunctive treatment for postoperative pain after cardiac surgery. Anesth Analg 2002; 95: 813-9, table of contents.
82. Pettersson PH, Jakobsson J, Owall A. Intravenous acetaminophen reduced the use of opioids compared with oral administration after coronary artery bypass grafting. J Cardiothorac Vasc Anesth 2005; 19: 306-9.
83. Boyle M, Nicholson L, O'Brien M, et al. Paracetamol induced skin blood flow and blood pressure changes in febrile intensive care patients: an observational study. Aust Crit Care 2010; 23: 208-14.
84. Bougie D, Aster R. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood 2001; 97: 3846-50.
85. Fenves AZ, Kirkpatrick HM 3rd, Patel VV, et al. Increased anion gap metabolic acidosis as a result of 5-oxoproline (pyroglutamic acid): a role for acetaminophen. Clin J Am Soc Nephrol 2006; 1: 441-7.
86. Electronic Medicines Compendium. Perfalgan 10mg/ml solution for infusion: summary of product characteristics. http://www.medicines. org.uk/EMC/medicine/14288/SPC/Perfalgan+10mg+ ml++Solution+for+Infusion/#PRODUCTINFO (accessed Jul 2011).
87. Beasley R, Clayton T, Crane J, et al. Association between paracetamol use in infancy and childhood and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6-7 years: analysis from Phase Three of the ISAAC program. Lancet 2008; 372: 1039-48.
88. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009; 43: 342-9.
89. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002; 40: 3-20.
90. Rumack BH. Acetaminophen misconceptions. Hepatology 2004; 40: 10-5.
91. Dart RC, Kuffner EK, Rumack BH. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther 2000; 7: 123-34.
92. Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001; 161: 2247-52.
93. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007; 11: 525-48, vi.
94. Claridge LC, Eksteen B, Smith A, et al. Acute liver failure after administration of paracetamol at the maximum recommended daily dose in adults. BMJ 2010; 341: c6764.